- Home
- FENC
as 03-28-2025 4:00pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 156.9M | IPO Year: | 2001 |
| Target Price: | $14.00 | AVG Volume (30 days): | 118.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $11.29 | Next Earning Date: | 03-10-2025 |
| Revenue: | $47,538,000 | Revenue Growth: | 123.69% |
| Revenue Growth (this year): | 28.99% | Revenue Growth (next year): | 63.21% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Raykov Rosty | FENC | Director | Mar 5 '25 | Sell | $6.79 | 10,000 | $67,900.00 | 68,725 | |
| RALLIS CHRIS A | FENC | Director | Feb 14 '25 | Sell | $6.82 | 1,186 | $8,088.52 | 53,020 | |
| Raykov Rosty | FENC | Director | Feb 5 '25 | Sell | $6.66 | 10,000 | $66,600.00 | 68,725 | |
| Raykov Rosty | FENC | Director | Jan 6 '25 | Sell | $6.08 | 10,000 | $60,800.00 | 68,725 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
GuruFocus.com
18 days ago
Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Thomson Reuters StreetEvents
18 days ago
Q4 2024 Fennec Pharmaceuticals Inc Earnings Call
MT Newswires
19 days ago
Wedbush Reviews Fennec Pharmaceuticals' Q4
Simply Wall St.
19 days ago
Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain
MT Newswires
19 days ago
Fennec Pharmaceuticals Q4 Loss Narrows
GlobeNewswire
19 days ago
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
GlobeNewswire
23 days ago
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
MT Newswires
2 months ago
Fennec Pharmaceuticals Announces Commercial Launch of Pedmarqsi in Germany
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.